Does the media prefer DYN or ETON?

In the previous week, Dyne Therapeutics had 11 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 17 mentions for Dyne Therapeutics and 6 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.79 beat Dyne Therapeutics' score of 0.69 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ETON or MANE?

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Veradermics. MarketBeat recorded 6 mentions for Eton Pharmaceuticals and 5 mentions for Veradermics. Eton Pharmaceuticals' average media sentiment score of 0.79 beat Veradermics' score of 0.19 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CRSP or ETON?

In the previous week, CRISPR Therapeutics and CRISPR Therapeutics both had 6 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.88 beat Eton Pharmaceuticals' score of 0.79 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ETON or EWTX?

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 7 mentions for Edgewise Therapeutics and 6 mentions for Eton Pharmaceuticals. Edgewise Therapeutics' average media sentiment score of 1.55 beat Eton Pharmaceuticals' score of 0.79 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ACAD or ETON?

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 7 mentions for ACADIA Pharmaceuticals and 6 mentions for Eton Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.21 beat Eton Pharmaceuticals' score of 0.79 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eton Pharmaceuticals (ETON) Competitors

$46.42 -2.61 (-5.32%)

Closing price 04:00 PM Eastern

Extended Trading

$46.38 -0.04 (-0.08%)

As of 06:28 PM Eastern

Compare

ETON vs. DYN, MANE, CRSP, EWTX, and ACAD

Should you buy Eton Pharmaceuticals stock or one of its competitors? MarketBeat compares Eton Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eton Pharmaceuticals include Dyne Therapeutics (DYN), Veradermics (MANE), CRISPR Therapeutics (CRSP), Edgewise Therapeutics (EWTX), and ACADIA Pharmaceuticals (ACAD).

How does Eton Pharmaceuticals compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Dyne Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

In the previous week, Dyne Therapeutics had 11 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 17 mentions for Dyne Therapeutics and 6 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.79 beat Dyne Therapeutics' score of 0.69 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Eton Pharmaceuticals	$86.93M	14.63	-$4.60M	-$0.07	N/A

Dyne Therapeutics presently has a consensus price target of $34.42, indicating a potential upside of 36.68%. Eton Pharmaceuticals has a consensus price target of $52.50, indicating a potential upside of 13.10%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Dyne Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Dyne Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-61.62%	-49.72%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Dyne Therapeutics beats Eton Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Veradermics?

Eton Pharmaceuticals (NASDAQ:ETON) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Veradermics has lower revenue, but higher earnings than Eton Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Veradermics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$86.93M	14.63	-$4.60M	-$0.07	N/A
Veradermics	N/A	N/A	N/A	-$1.32	N/A

Eton Pharmaceuticals presently has a consensus target price of $52.50, indicating a potential upside of 13.10%. Veradermics has a consensus target price of $153.00, indicating a potential upside of 45.65%. Given Veradermics' stronger consensus rating and higher probable upside, analysts clearly believe Veradermics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Veradermics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Veradermics' return on equity of 0.00% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Veradermics	N/A	N/A	N/A

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Veradermics. MarketBeat recorded 6 mentions for Eton Pharmaceuticals and 5 mentions for Veradermics. Eton Pharmaceuticals' average media sentiment score of 0.79 beat Veradermics' score of 0.19 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Eton Pharmaceuticals and Veradermics tied by winning 7 of the 14 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

In the previous week, CRISPR Therapeutics and CRISPR Therapeutics both had 6 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.88 beat Eton Pharmaceuticals' score of 0.79 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has a net margin of -1.70% compared to CRISPR Therapeutics' net margin of -13,856.54%. Eton Pharmaceuticals' return on equity of -5.68% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

Eton Pharmaceuticals has higher revenue and earnings than CRISPR Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,318.70	-$581.60M	-$6.22	N/A
Eton Pharmaceuticals	$86.93M	14.63	-$4.60M	-$0.07	N/A

CRISPR Therapeutics presently has a consensus price target of $67.78, indicating a potential upside of 41.23%. Eton Pharmaceuticals has a consensus price target of $52.50, indicating a potential upside of 13.10%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe CRISPR Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

CRISPR Therapeutics has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

CRISPR Therapeutics beats Eton Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Edgewise Therapeutics?

Eton Pharmaceuticals (NASDAQ:ETON) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Eton Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 7 mentions for Edgewise Therapeutics and 6 mentions for Eton Pharmaceuticals. Edgewise Therapeutics' average media sentiment score of 1.55 beat Eton Pharmaceuticals' score of 0.79 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Eton Pharmaceuticals has higher revenue and earnings than Edgewise Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$86.93M	14.63	-$4.60M	-$0.07	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Eton Pharmaceuticals presently has a consensus target price of $52.50, suggesting a potential upside of 13.10%. Edgewise Therapeutics has a consensus target price of $48.75, suggesting a potential upside of 26.85%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Edgewise Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Edgewise Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Edgewise Therapeutics beats Eton Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Eton Pharmaceuticals' net margin of -1.70%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

ACADIA Pharmaceuticals currently has a consensus price target of $32.31, indicating a potential upside of 24.88%. Eton Pharmaceuticals has a consensus price target of $52.50, indicating a potential upside of 13.10%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe ACADIA Pharmaceuticals is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.67
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

ACADIA Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Eton Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.13	$391M	$2.20	11.76
Eton Pharmaceuticals	$86.93M	14.63	-$4.60M	-$0.07	N/A

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 7 mentions for ACADIA Pharmaceuticals and 6 mentions for Eton Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.21 beat Eton Pharmaceuticals' score of 0.79 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ACADIA Pharmaceuticals beats Eton Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

Get Eton Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ETON vs. The Competition

Export

Metric	Eton Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.27B	$11.71B	$6.83B	$12.41B
Dividend Yield	N/A	2.72%	2.59%	10.11%
P/E Ratio	-663.05	793.97	281.83	23.65
Price / Sales	14.63	745.94	572.65	81.09
Price / Cash	9,285.77	74.78	69.88	58.30
Price / Book	47.37	10.35	10.93	5.84
Net Income	-$4.60M	$2.82B	$3.49B	$336.16M
7 Day Performance	8.99%	-0.29%	-0.29%	0.03%
1 Month Performance	28.23%	-3.38%	-2.58%	-5.22%
1 Year Performance	227.82%	172.45%	66.21%	17.37%

Eton Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ETON Eton Pharmaceuticals	3.8158 of 5 stars	$46.42 -5.3%	$52.50 +13.1%	+237.7%	$1.27B	$86.93M	N/A	20	Upcoming Earnings Analyst Forecast
DYN Dyne Therapeutics	3.4549 of 5 stars	$25.94 +1.2%	$34.17 +31.7%	+159.6%	$4.84B	N/A	N/A	100	Earnings Report Analyst Forecast
MANE Veradermics	2.4274 of 5 stars	$110.99 -0.4%	$153.00 +37.9%	N/A	$4.62B	N/A	N/A	19	Lockup Expiration
CRSP CRISPR Therapeutics	2.8767 of 5 stars	$46.22 -1.1%	$67.78 +46.7%	-16.0%	$4.45B	$3.51M	N/A	460	Upcoming Earnings
EWTX Edgewise Therapeutics	3.7399 of 5 stars	$40.94 -1.6%	$48.75 +19.1%	+189.0%	$4.40B	N/A	N/A	60	News Coverage Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ETON) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eton Pharmaceuticals (ETON) Competitors

ETON vs. DYN, MANE, CRSP, EWTX, and ACAD

How does Eton Pharmaceuticals compare to Dyne Therapeutics?

Summary

How does Eton Pharmaceuticals compare to Veradermics?

Summary

How does Eton Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Eton Pharmaceuticals compare to Edgewise Therapeutics?

Summary

How does Eton Pharmaceuticals compare to ACADIA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eton Pharmaceuticals (ETON) Competitors

ETON vs. DYN, MANE, CRSP, EWTX, and ACAD

How does Eton Pharmaceuticals compare to Dyne Therapeutics?

Which has more risk and volatility, DYN or ETON?

Does the media prefer DYN or ETON?

Which has higher valuation & earnings, DYN or ETON?

Do analysts prefer DYN or ETON?

Is DYN or ETON more profitable?

Do institutionals and insiders have more ownership in DYN or ETON?

Summary

How does Eton Pharmaceuticals compare to Veradermics?

Do institutionals and insiders have more ownership in ETON or MANE?

Which has stronger earnings & valuation, ETON or MANE?

Do analysts recommend ETON or MANE?

Is ETON or MANE more profitable?

Does the media prefer ETON or MANE?

Summary

How does Eton Pharmaceuticals compare to CRISPR Therapeutics?

Does the media prefer CRSP or ETON?

Is CRSP or ETON more profitable?

Which has preferable valuation & earnings, CRSP or ETON?

Do analysts prefer CRSP or ETON?

Which has more volatility & risk, CRSP or ETON?

Do institutionals & insiders believe in CRSP or ETON?

Summary

How does Eton Pharmaceuticals compare to Edgewise Therapeutics?

Which has more volatility & risk, ETON or EWTX?

Does the media favor ETON or EWTX?

Which has higher earnings & valuation, ETON or EWTX?

Do analysts recommend ETON or EWTX?

Is ETON or EWTX more profitable?

Do insiders and institutionals have more ownership in ETON or EWTX?

Summary

How does Eton Pharmaceuticals compare to ACADIA Pharmaceuticals?

Do insiders & institutionals have more ownership in ACAD or ETON?

Is ACAD or ETON more profitable?

Do analysts prefer ACAD or ETON?

Which has more risk and volatility, ACAD or ETON?

Which has higher valuation & earnings, ACAD or ETON?

Does the media favor ACAD or ETON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools